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Abstract 
Nuclear depletion of TDP-43, an RNA binding protein which serves to protect the transcriptome 
by repressing aberrant splicing, may underlie neurodegeneration in amyotrophic lateral 
sclerosis (ALS). As multiple functions have been ascribed to TDP-43, whether splicing repression 
is its major role in motor neurons – that may be compromised in ALS – remains to be 
established. Here, we show that TDP-43 mediated splicing repression is central to the 
physiology of motor neurons. To validate TDP-43 mediated splicing repression as a therapeutic 
target, an AAV9-mediated gene delivery approach was employed to deliver a chimeric protein 
comprised of the N-terminal RNA recognition domain of TDP-43 fused to an unrelated splicing 
repressor (RAVER1) to mice lacking TDP-43 in motor neurons. This strategy allowed long-term 
expression of the repressor without any untoward effects, delayed the onset and slowed the 
progression of disease, and extended survival. In treated mice, evidence of aberrant splicing 
was markedly decreased and accompanied by amelioration of motor neuron loss. These 
findings establish that splicing repression is a principal role of TDP-43 in motor neurons and 
support the idea that loss of TDP-43-mediated splicing repression represents a key pathogenic 
mechanism underling motor neuron loss, validating a novel mechanism-based therapeutic 
strategy for ALS. 
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Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease, is the most 
common motor neuron disease (Table 1) characterized by the death of upper and lower motor 
neurons(Cleveland, Rothstein, Cleveland, & Rothstein, 2001; del Aguila, Jr, McGuire, Koepsell, & 
van Belle, 2003). Patients with ALS show progressively worsening weakness, spasticity, muscle 
atrophy, and an eventual loss of voluntary muscle control(Cleveland et al., 2001; del Aguila et 
al., 2003). With an incidence rate of 2 per 100,000 people, the average life expectancy following 
diagnosis of this incurable disease is only 2-5 years, with most deaths occurring due to 
respiratory failure(Cleveland et al., 2001; del Aguila et al., 2003; Julien, 2001).  The genetic 
underpinnings of ALS are complex, with only about 5-10% of ALS cases showing a recognizable 
family history of disease, termed ‘familial’ ALS (fALS), and the remaining 90-95% of cases 
termed ‘sporadic’ ALS (sALS). While the pathophysiology of ALS was described by Jean-Martin 
Charcot in 1874, to this day, the molecular mechanisms underlying motor neuron death in ALS 
still remain unknown. Nevertheless, important work over the last several decades has provided 
valuable insights into the causes and progression of this currently incurable disease. 
In 1993, it was discovered that mutations in the Cu-Zn superoxide dismutase (SOD1) 
gene were associated with ~20% of fALS, representing ~2% of all ALS cases(Jones, Brock, 
Chancellor, Warlow, & Swingler, 1993; Rosen et al., 1993). While the exact mechanisms through 
which mutant SOD1 affects motor neuron health are not fully elucidated to this day, this 
discovery allowed for the generation of the first transgenic mouse models (SOD1G93A mice), 
allowing researchers new opportunities to explore disease mechanisms and potential 




other genes, such as ALS2, OPTN, VCP, TBK1, and UBQLN, among others, were associated with 
ALS and consequently have also been studied in animal models (Table 2). However, as these 
genetic mutations, taken together, only represent a small fraction of total ALS patients, our 
understanding of the molecular underpinnings of most cases of ALS still remained minimal. 
Furthermore, many of these genes affected diverse pathways and cellular functions, 
complicating efforts at identifying a unifying downstream mechanism of motor neuron death in 
ALS that could be targeted for therapeutic intervention.  
One major breakthrough in the ALS field was made in 2006, when it was discovered that 
in neurons and oligodendrocytes of patients with sALS, Tar DNA-binding protein 43 (TDP-43, 
encoded by the gene TARDBP), an essential, highly-conserved RNA binding protein(Sephton et 
al., 2010; L. S. Wu et al., 2010), unusually depletes from the nucleus and aggregates in 
ubiquitinated cytoplasmic inclusions(Neumann et al., 2006). These TDP-43 positive inclusions 
were visible in ~95% of patients with sALS and ~50% of patients with frontotemporal dementia 
(FTD), the second most common type of young-onset dementia with an incidence rate of 10-30 
per 100,000 people(Arai et al., 2006a; Sieben et al., 2012). Two important implications could be 
drawn from this finding. Firstly, this observation, coupled with clinical evidence of symptom 
overlap between ALS and FTD(Lomen-Hoerth, Anderson, & Miller, 2002), has led to the idea that 
these two diseases exist on a spectrum (termed ALS/FTD). Secondly, the fact that TDP-43 
mislocalization could be observed in a vast majority of total ALS cases suggested that this 
protein plays a fundamental role in disease. Supporting this claim was the subsequent discovery 
that missense mutations in TDP-43, which mostly cluster within its C-terminal domain, are 




genetic mutations associated with familial ALS/FTD, such as UBQLN, ATXN2, SQSTM1, and TBK1 
are associated with TDP-43 pathology (Table 2). Of particular note is the observation that TDP-
43 mislocalization is observed in patients carrying a hexanucleotide repeat expansion in 
C9ORF72, recently discovered to be the most common genetic cause of ALS/FTD(Chew et al., 
2015).  Furthermore,TDP-43 pathology is evident in a subset of patients with inclusion body 
myositis (IBM) (Salajegheh et al., 2009) and Alzheimer’s disease (AD) (Amador-Ortiz et al., 2007; 
Josephs et al., 2014). TDP-43 pathology is notably absent in neurons of patients with SOD1 
mutations(Mackenzie et al., 2007), suggesting that motor neuron death may occur through 
distinct mechanisms in SOD1-ALS and potentially necessitating the division of ALS/FTD into 
different sub-types. Nevertheless, these observations support the notion that in the vast 
majority of ALS/FTD cases, TDP-43 mislocalization is central to disease pathogenesis and 
presents a final common pathogenic pathway. 
 
Gain and Loss of Function Models of TDP-43 Pathology 
To date, the precise mechanism underlying TDP-43 pathology in ALS/FTD remains 
unclear, as loss of nuclear function, cytoplasmic toxic gain of function, or both, may contribute 
to disease. Animal studies have provided some insight into this problem. Initial efforts focused 
on studies of transgenic wild-type human and ALS-linked mutant human TDP-43 overexpression 
models(Ash et al., 2010; Shan, Chiang, Price, & Wong, 2010; Wils et al., 2010; Xu et al., 2010). 
Overexpression of both wild-type and mutant TDP-43 in multiple model systems results in age-
dependent neurodegeneration and behavioral deficits consistent with the phenotype of 




pathological features of ALS, such as cytoplasmic aggregation. Furthermore, as TDP-43 binds to 
its own 3’ untranslated region (UTR) to tightly autoregulate its own transcript levels, transgenic 
mutant TDP-43 overexpression can suppress endogenous mouse Tdp-43(Winton et al., 2008). 
Recent research demonstrated that transgenic cytoplasmic accumulation of mutant TDP-43 
with a nonfunctional nuclear localization sequence (NLS) in neurons of mice resulted in 
depletion of endogenous nuclear Tdp-43, raising the question as to whether the observed 
neurodegenerative phenotype was due to cytoplasmic accumulation or nuclear loss of TDP-
43(Spiller et al., 2016). Hence, the precise contribution of toxic gain of function of TDP-43 has 
remained unclear.  
Subsequent research has suggested that depletion of nuclear TDP-43 plays a critical role 
in motor neuron degeneration as well. While global knockout of TDP-43 is embryonically 
lethal(Kraemer et al., 2010), our lab and others have demonstrated that post developmental 
tissue-specific deletion of TDP-43 also recapitulates the age-dependent progressive 
neurodegeneration of ALS/FTD(Feiguin et al., 2009; Kraemer et al., 2010; Schmid et al., 2013; 
Vanden Broeck, Callaerts, & Dermaut, 2014; C. Yang, Wang, Qiao, Yang, Aliaga, Qiu, Tan, 
Salameh, McKenna-Yasek, Smith, Peng, Moore, Brown, Cai, & Xu, 2014a; Zuo-Shang Xu, 2012). 
Interestingly, Vatsavayai and colleagues reported nuclear clearance of TDP-43 – but not 
cytoplasmic TDP-43 aggregates – in a brain biopsy of a patient five years prior to their first 
symptoms of FTD(Vatsavayai et al., 2016a). Brain tissue examined at autopsy, 8 years after 
symptom onset, did contain cytoplasmic TDP-43 inclusions, suggesting that nuclear loss of TDP-




onset of clinical symptoms. Therefore, research exploring the contribution of loss of nuclear 
TDP-43 function to neuronal survival is of critical importance.   
Recent work has uncovered evidence of impaired nucleocytoplasmic trafficking in 
several neurodegenerative diseases, including ALS/FTD(K. Zhang et al., 2015). The interplay 
between nucleocytoplasmic transport, cytoplasmic TDP-43 accumulation, and nuclear depletion 
of TDP-43 is complex; while TDP-43 mislocalization may be a downstream consequence of 
defective nucleocytoplasmic transport, newer evidence suggests that cytoplasmic aggregation 
of TDP-43 itself impairs the nuclear pore complex and nucleocytoplasmic transport(Chou et al., 
2018). Ultimately, both toxic gain of function and loss of function of TDP-43 are thought to play 
important roles in disease.  
 
TDP-43 Represses Aberrant Splicing 
In order to better understand the contribution of pathological TDP-43 mislocalization to 
disease, one important step is to better understand the essential function(s) of this protein in 
neurons. TDP-43 is thought to play important roles in several essential cellular processes in 
both the nucleus and cytoplasm, including cellular stress response pathways(McDonald et al., 
2011), mRNA delivery to dendritic or axonal compartments(Alami et al., 2014), or phase 
separation of membrane-less organelles(Gopal, Nirschl, Klinman, & Holzbaur, 2017; Molliex et 
al., 2015).  As a member of the heterogenous ribonuclear protein (hnRNP) family, TDP-43 is 
concentrated in transcriptionally active euchromatin regions(Casafont, Bengoechea, Tapia, 
Berciano, & Lafarga, 2009), and is thought to regulate alternative splicing(Buratti et al., 2001; 




many proteins and RNAs, potentially regulating numerous pathways and complicating efforts at 
developing mechanism-based therapies(Fiesel et al., 2010; Freibaum, Chitta, High, & Taylor, 
2010). 
Recently, our lab discovered that TDP-43 is the founding member of a class of proteins 
that act as a guardian of the transcriptome by repressing aberrant splicing (Ling, Pletnikova, 
Troncoso, & Wong, 2015), a function that is compromised in cases of neurodegenerative 
diseases with TDP-43 pathology(Jeong et al., 2017; Sun et al., 2017a). Depletion of TDP-43 leads 
to expression of transcripts with abnormal incorporation of aberrant ‘cryptic’ exons in UG-rich, 
normally intronic regions. Advancements in the resolution of RNA-sequencing technologies 
have only recently allowed for transcriptomic analysis to uncover these previously elusive 
splicing changes. Evidence of cryptic exon incorporation can be observed in cases of ALS/FTD, 
IBM, and AD displaying TDP-43 pathology, providing a useful biomarker for loss of nuclear TDP-
43 function and suggesting that loss of this splicing repression function may underlie disease 
pathogenesis(Jeong et al., 2017; LaClair et al., 2016; Sun et al., 2017b).  
Subsequent analysis of the cryptic exon profile in different cell types revealed that due 
to the non-conserved nature of the UG-rich intronic regions, the exact transcripts affected by 
loss of TDP-43 function are highly variable between organisms and cell types; hence, TDP-43 
loss may impair cell type-specific pathways in unique ways(Jeong et al., 2017). However, 
impaired splicing repression, leading to the loss of transcriptional fidelity, may represent a 
common, upstream cause of neuronal death in ALS/FTD. While the exact targets affected by 
compromised splicing repression in TDP-43 knockout tissues is variable, the splicing repression 




that restores TDP-43’s function may be more viable than one aimed at restoring any one 
particular transcript(Jeong et al., 2017). Since TDP-43 is involved in multiple other intracellular 
roles, however, it remains unknown whether splicing repression is a major function of TDP-43 
in motor neurons. If so, restoring this function in affected motor neurons would represent a 
promising new mechanism-based therapeutic approach for ALS/FTD and potentially for other 
human diseases with TDP-43 pathology. 
Using a mouse model system, we establish here that TDP-43-mediated splicing 
repression is central to the physiology of motor neurons. First, we confirm in two different 
mouse models that postnatal deletion of Tdp-43 in either forebrain excitatory neurons or motor 
neurons results in progressive, age-dependent neurodegeneration. In tissues from both mouse 
models, we observe evidence of compromised splicing repression. Next, using an AAV9-
mediated gene delivery approach(Foust et al., 2010), we validate a mechanism-based 
therapeutic strategy to restore TDP-43-mediated splicing repression to attenuate 
neurodegeneration caused by the loss of nuclear TDP-43 function. These findings provide a 
potential molecular basis of TDP-43 pathology in motor neurons and establish a proof-of-














All mouse procedures were performed in accordance with the National Institutes of Health 
Guide for the Care and Use of Laboratory Animals and were approved by the Johns Hopkins 
University Animal Care and Use Committee. 
We crossbred our previously described conditional Tardbp knockout mice (Chiang et al, PNAS 
2010) (TardbpF/F, Jax stock 017591) with ChAT-IRES-Cre transgenic mice on a C57BL/6J 
background (Jax stock 006410) to obtain a cohort of ChAT-IRES-Cre;TardbpF/+ mice. These were 
subsequently crossed again with TardbpF/F mice to generate the final cohort of ChAT-IRES-
Cre;TardbpF/+ (control) and ChAT-IRES-Cre;TardbpF/F (Tdp-43 knockout) mice. All mice were 
housed under a 12L:12D daily cycle and managed by Johns Hopkins University Research Animal 
Resources (RAR).  
We depleted TDP-43 in the forebrains of adult mice in a similar manner by crossing our 
TardbpF/F mice to those CaMKIIa-CreER mice to generate tamoxifen-inducible conditional Tardbp 
knockout mice (CaMKIIa-CreER;TardbpF/F mice, termed cT) mice, allowing tamoxifen-induced 
recombination in excitatory forebrain neurons at maturity. Oral tamoxifen citrate was 
administered to all animals in the feed (Harlan Teklad) at an average 40 mg/kg/day for a 4week 
period beginning at p42-46, and mice were singly housed during this period to monitor 
tamoxifen-feed intake.   




CTR was cloned as previously described(Ling et al., 2015). AAV9 packaging was performed by 
Virovek (Hayward CA), and CTR or GFP expression was independently confirmed by HeLa cell 
transduction and western blot prior to all experiments. 
Intracerebroventricular (ICV) Injection  
All injections were performed on mouse pups within 8 hours of birth. Pups were cryo-
anaesthetized on wet ice for no longer than 2 minutes. A latex barrier between pups and ice 
prevented skin damage. A sterile, single-use pulled glass needle (Drummond microcaps, 41 mm 
length, approx. 0.5 mm minimum diameter) was penetrated 3mm into the lateral ventricle of 
each cryo-anaesthetized mouse pup to slowly deliver 3 µl of AAV9 (1E1013 vg/ml) carrying either 
our chimeric splicing repressor protein, termed CTR, or GFP into the lateral ventricles over 15 
seconds; solutions contained 0.05% trypan blue dye for localization. Pups recovered under a 
heat lamp with bedding from their home cage in order to restore scent, after which they were 
returned to their mother cage and monitored after 6 and 12 hours and daily afterwards. A 
successful injection was identified by dye-induced darkening of the spinal column at 6 hours 
post-injection. Approximately 80% of pups successfully recovered from injection, with 10% 
insufficiently recovering from anesthesia at p0-p1 and 10% displaying signs of hydrocephaly at 
p14-p21. All pups showing signs of distress at any time following recovery were euthanized.    
Sample Size 
Sample sizes for all cohorts examined in the CTR rescue study are presented in Table 3. All 
litters were injected prior to genotyping. For motor function and survival analyses, a total of 40 
mice from 8 litters were injected for cohort 1. Every pup in each litter was injected at random 




each litter received either CTR or GFP. A total of 8 ChAT-IRES-Cre;TardbpF/+ mice were injected 
with GFP, 8 ChAT-IRES-Cre;TardbpF/+ mice were injected with CTR, 11 ChAT-IRES-Cre;TardbpF/F 
were injected with GFP, and 11 ChAT-IRES-Cre;TardbpF/F mice were injected with CTR. The size 
of cohort 1 was sufficiently powered to measure a mean survival increase of 50% with 25% 
standard deviation (1-β = 0.994). We then replicated our results by injecting a second cohort of 
mice from the same breeder pairs, termed ‘cohort 2’. Each litter in cohort 2 received the 
opposite payload as its cohort 1 counterpart. Two additional cohorts, each from the same 
breeder pairs, were bred and injected for analysis of spinal cord pathology at p90 (pathology 
analysis cohort) and for injection of an AAV9 vector carrying only the N-terminal fragment of 
TDP-43 as another control (N-terminal fragment cohort).  
Hanging Wire Test 
Hanging wire tests(Deacon, 2013) were performed weekly beginning at p30. Investigators were 
blinded to the treatment group of each animal. Each mouse was placed on the center of a 
metal grid that then was shaken gently to prompt the mouse to hold on before being turned 
upside down 30 cm over an empty cage. Each mouse was allowed up to three attempts to hold 
on to the inverted grid for an arbitrary maximum of 60 seconds. Mice were given >2 minutes of 
rest between attempts, and the best attempt was used for analyses. 
Accelerating Rotarod Test 
Rotarod tests(Deacon, 2013) were performed once every two weeks with an initial 
acclimatization session beginning at p30. Investigators were blinded to the treatment group of 
each animal. Mice were placed on the apparatus (Rotamex 5, Columbus Instruments) with a rod 




was recorded. Each mouse was given three attempts with >30 minutes of rest between 
attempts, and the best attempt was used for analyses.  
Elevated Plus Maze Test 
The elevated plus maze (San Diego Instruments) test was performed to evaluate levels of 
anxiety-like behavior. This maze was made of stainless steel and consisted of two closed arms 
measuring 19.5 inches in length × 4 inches in width × 15.5 inches in height and two open arms 
measuring 19.5 inches in length × 4 inches in width. These arms were connected by a 4 × 4-inch 
platform. Each mouse was placed on the center platform and remained in the maze for 5 min. 
Number of visits and time spent in the closed arms and open arms was measured(LaClair et al., 
2016). 
Spontaneous Alternation Y Maze Test 
The Y-maze has three arms (18.5 inches in length × 2.5 inches in width × 1 inch in height) 
radiating at equal angles from a central platform. Mice were place into the end of one arm and 
allowed to explore freely for 5 min. The sequence of arm entries was recorded. The 
spontaneous alternation behavior was calculated as the number of triads containing entries 
into all three arms divided by the maximum possible alternations(LaClair et al., 2016). 
Survival 
Upon showing symptoms of hindlimb paralysis, mice were provided wet chow and Dietgel on 
the cage floor. End-stage was defined as a failure of a mouse to right itself within 10 seconds 
when placed on its back on the cage floor and was tested daily after hindlimb paralysis was 
observed. Investigators were blinded to the treatment group of each animal. All mice were 





Total RNA was extracted from hippocampi of 3 month old female CamKIIa-Cre;TardbpF/F 
(knockout) and littermate control mice (CamKIIa-Cre;TardbpF/+) using TRIzol (Life Tech.) and 
RNeasy Mini kits (Qiagen).  Three control brains and three knockout brains were analyzed, and 
all mice were female. Total RNA was isolated using RNeasy Mini Kit (Qiagen). cDNA was 
synthetized using RevertAid First Strand cDNA Synthesis Kit (Thermo Scientific) with random 
primers. Primers used to amplify cryptic exons were as follows: Ap3b2 F: 
AGCCAGAATATGGCCACGAC; Ap3b2 R: CACTATGATGGGCACACGGA; Camk1G F:  
CTGGCCAAGATCACAGACTGG; CamK1G R: CTGTGTAGACACCACGCTCT. 
Quantitative PCR 
Whole spinal cords of p45 ChAT-IRES-Cre;TardbpF/+ and ChAT-IRES-Cre;TardbpF/F mice were 
dissected, titurated using a 1 mL syringe with a 20-gauge needle, and placed in TRIzol. RNA 
from whole fly heads was extracted in a similar way. Total poly-A-containing messenger RNA 
was extracted using a RNeasy Mini kit (Qiagen) protocol under RNAse-free conditions and 
converted to cDNA using the Protoscript II First Strand cDNA Synthesis Kit (NEB). Quantitative 
PCR for cryptic exon mRNA was performed using the PowerUp SYBR Green protocol (Applied 
Biosystems) with the following primers: GGCT F: GAGGGGTGTTGGAAGGCTGT; GGCT R: 
TACCACTCCCCACACTTCGT; SYNJ2BP F: CTCCAACGACAGTGGCATCT; SYNJ2BP R: 
TCTTCCTGAGGACCTCCGTT; IFT81 F: AAGTGCGAGGACTTCGTGAG; IFT81 R: 
CAGCGATCTGTCTGCTTTGC; GAPDH F: AGGTCGGTGTGAACGGATTTG; GAPDH R: 
GGGGTCGTTGATGGCAACA; TBP F: AAGGGAGAATCATGGACCAG; TBP R: 




experiment independently repeated three times. Relative transcript levels were calculated in 
Microsoft Excel according to the formula: (POWER(2, −(Ct mean cryptic exon 
target)))/(POWER(2, –(AVERAGE(Ct mean TBP, Ct mean GAPDH))). 
Histological and Immunohistochemical Analysis 
P90 mice from the pathology analysis cohort were anaesthetized and perfused with 4% 
paraformaldehyde. The cervical (C5-C8) and lumbar (L1-L3) enlargements and their 
corresponding spinal ganglions from each mouse were dissected and post-fixed for 24 hours. 
Spinal ganglions were embedded in epoxy resin and sagittally sectioned at 1 µm thickness. 
Spinal cords were embedded in paraffin and sagittally sectioned at 10 µm thickness. Sections 
were stained with hematoxylin/eosin or Cresyl violet for histological analysis. 
For immunohistochemical analysis, sections were deparaffinized and incubated in 10 mM citric 
acid at 95 C for 10 minutes followed by a 30-minute incubation in 0.3% hydrogen peroxide in 
methanol to quench endogenous peroxidase activity. Normal goat serum (5%) in PBS-T was 
used to block nonspecific binding, after which primary antibody in blocking buffer was applied 
to each section overnight at 4 C in a humid chamber. Secondary antibodies were applied at 
room temperature for 2 hours. A Vectastain Universal Elite ABC kit (Vector Laboratories) was 
used to amplify signal.  
Sections were stained with the following primary antibodies: Human-specific N-terminus TDP-
43 (hTDP43, 1:500; AB57105, Abcam), Choline acetyltransferase (ChAT, 1:1000; AB144, 
Millipore), C-terminus TDP-43 (1:500; 12892-1AP, Proteintech), microtubule-associated protein 
2 (Map2, 1:1,000; AB5622, Millipore), phosphorylated neurofilament (Smi31, 1:1,000; 




molecule 1(IBA1, 1:500; 10904-1AP, Proteintech), glial fibrillary acidic protein (GFAP, 1:500; 
AB7260, Abcam), phosphorylated tau (Tau422, 1:1000; AB79415, Abcam). 
Immunoblot Analysis 
Whole spinal cords from p90 mice were flushed and homogenized using a 1 mL syringe with a 
20-gauge needle in cold RIPA buffer with protease inhibitor cocktail (Roche). Protein 
concentration in the supernatants was determined via BCA assay (Pierce), and 10 μg protein 
was loaded on a 10% Bis-Tris SDS-PAGE gel (Novex) and transferred to a PVDF membrane, 
which was probed with the following antibodies: N-terminal TDP-43 (1:2000; 10782-2-AP, 
Proteintech), β-tubulin III (1:20,000; T2200, Sigma).  
Data and Statistical Analysis 
Histological and RNA data was analyzed using the unpaired, two-tailed Student’s t-test with 
Tukey’s multiple comparison where appropriate, and one-way analysis of variance (ANOVA) 
test using Stata 10 for Mac (Statacorp) and Graphpad Prism for Mac (Graphpad Software). 
Mouse hanging wire, rotarod, and weights were analyzed using two-way ANOVA with Tukey’s 
multiple comparison. Kaplan-Meier survival curves were analyzed using the log-rank test. P 













Conditional Deletion of Tdp-43 Results in Age-Dependent Neurodegeneration 
As a first step, to determine whether cell type-specific conditional deletion of Tdp-43 can lead 
to age-dependent neurodegeneration, a major phenotype of ALS/FTD, we took advantage of 
our Tdp-43 conditional knockout mice, in which exon 3 of Tdp-43 was flanked by loxp 
sites(Chiang et al., 2010) (TardbpF/F), and crossbred them with a choline acetyltransferase 
(ChAT) dependent Cre driver line(Rossi et al., 2011) (ChAT-IRES-Cre) to generate a line lacking 
Tdp-43 in >95% of ChAT-positive spinal motor neurons by p30 (ChAT-IRES-Cre;TardbpF/F mice, 
Figure 1A). Homozygous cell type-specific knockout is necessary because global Tdp-43 deletion 
is embryonically lethal, and heterozygous knockout mice show normal levels of Tdp-43 due to 
autoregulation(Chiang et al., 2010; Kraemer et al., 2010). Our Tdp-43 conditional knockout mice 
showed progressive, age-dependent loss of cervical and lumbar motor neurons and a reduction 
number and caliber of ventral, but not dorsal, root axons (Figures 2, 10, 11). ChAT-IRES-
Cre;TardbpF/F mice also exhibited reduced body weight and showed tremor, hindlimb 
weakness, and paralysis with mortality occurring around 8-10 months (Figures 8A, red line). 
This phenotype is consistent with other, previously reported motor neuron Tdp-43 knockout 
mouse models(Iguchi et al., 2013; L. S. Wu, Cheng, & Shen, 2012; C. Yang, Wang, Qiao, Yang, 
Aliaga, Qiu, Tan, Salameh, McKenna-Yasek, Smith, Peng, Moore, Brown, Cai, & Xu, 2014b). As 
predicted, we found evidence of aberrant splicing and cryptic exon incorporation in the spinal 
cords of p45 ChAT-IRES-Cre;TardbpF/F mice through quantitative RT-PCR (Figure 12, red bars). 
As our ChAT-dependent Cre driver expresses before ~p30 (Figure 1B), we then 




age-dependent neurodegeneration, or is rather due to residual effects from motor neuron 
neurodevelopmental defects. Additionally, we wondered if Cre-mediated Tdp-43 excision from 
excitatory forebrain neurons could be used to model TDP-43 dysfunction in FTD or AD as well. 
To answer these questions, we took advantage of another driver line (CaMKIIa-CreER) to 
generate CaMKIIa-CreER;TardbpF/F mice (Figure 3A), in which tamoxifen-induced recombination 
at p42 resulted in depletion Tdp-43 in ~80% of post-developmental excitatory pyramidal 
neurons in the hippocampus and ~40% in the cortex (Figure 3B-D). Age-dependent loss of these 
forebrain neurons mimics observations of neuronal loss in patients with FTD or AD. Like our 
motor neuron Tdp-43 knockout mice, our forebrain knockout mice also showed progressive, 
age-dependent loss of cortical and hippocampal neurons, reduced brain volume, and worsening 
behavioral and cognitive abnormalities (Figures 4-5). RT-PCR analysis of hippocampal lysate 
from non-inducible p90 mice under the same promoter (CaMKIIa-Cre;TardbpF/F mice) confirmed 
the incorporation of aberrant cryptic exons in knockout mice (Figure 6). Taken together, these 
results confirm that postnatal deletion of neuronal Tdp-43 in mice leads to age-dependent 
neurodegeneration, a major phenotype observed in ALS/FTD or AD.     
 
A Chimeric Protein (CTR) Restores Splicing Repression in Mice lacking Tardbp in Motor 
Neurons 
We previously found that TDP-43 maintains splicing fidelity by repressing previously 
unannotated ‘cryptic’ exons (Ling et al., 2015). TDP-43 mediated splicing repression can be 
restored using a chimeric protein, termed CTR, consisting of the RNA-recognizing N-terminal 




repressor, RAVER1 (Figure 7C)(Gromak et al., 2003; Ling et al., 2015; Rideau et al., 2006). The C-
terminal domain of TDP-43, a region that harbors most disease-causing mutations and contains 
a low-complexity prion-like domain thought to be potentially responsible for pathological 
cytoplasmic TDP-43 aggregation in ALS/FTD(Conicella, Zerze, Mittal, & Fawzi, 2016), was 
replaced by the splicing repression domain from RAVER1, a region with no sequence similarity 
to TDP-43. Previous work in our lab has validated that the CTR fusion protein is able to enter 
the nucleus and repress splicing as predicted in a cell culture model(Ling et al., 2015). However, 
since multiple roles have been ascribed to TDP-43(Buratti et al., 2001; Casafont et al., 2009; 
Fiesel et al., 2010; Freibaum et al., 2010; Gendron, Josephs, & Petrucelli, 2010; Ling et al., 2015; 
Ou, Wu, Harrich, Garca-Martnez, & Gaynor, 1995), it is not known whether splicing repression 
is central to the physiology of mammalian motor neurons in vivo. To determine whether 
splicing repression is a major role of TDP-43 in motor neurons, we elected to use AAV9 to 
deliver CTR to central neurons of mice lacking TDP-43 in spinal motor neurons, a model which 
exhibits age dependent motor neuron disease accompanied by evidence of incorporation of 
TDP-43 cryptic exons (see above).  
 To deliver our fusion protein to motor neurons in mice, we selected adeno-associated 
virus serotype 9 (AAV9) as our vector due to its neuronal tropism in neonatal mice, minimal 
immunogenicity, and episomal persistence(McMenamin & Wood, 2010; Weinberg, Samulski, & 
McCown, 2013). AAV technology has also been previously validated as safe and effective in 
human clinical trials, thereby improving the therapeutic relevance of our strategy(Janson et al., 
2002; Kaplitt et al., 1994). Intracerebroventricular (ICV) injections allowed us to effectively 




throughout the spinal cord. Neonatal (rather than adult) mice were treated for three reasons: 
Firstly, for poorly understood reasons, the neuronal tropism of AAV9 appears strongest in 
neonates(Foust et al., 2009; Howard, Powers, Wang, & Harvey, 2008); secondly, by introducing 
the CTR protein at an early age, we hoped to maximize the observed rescue effect; lastly, using 
neonatal mice necessitated a minimal viral dose, thereby allowing us to increase our sample 
size for all experiments. 
Perinatal unilateral intracerebroventricular injection of AAV9 (3x1010 vg/mouse) carrying 
our CTR chimeric construct (Figure 7C) under a ubiquitous chicken beta-actin hybrid (CBhA) 
promoter selected for its robust long-term expression(Kawamoto, Shi, Nitta, Miyazaki, & Allen, 
2005) resulted in CTR protein expression in 50-60% of cervical and lumbar motor neurons, first 
observed at p30 and persisting to at least 8 months in mice (Figure 7A). Transgenic expression 
was strongest in the nucleoplasm, with no evidence of cytoplasmic CTR aggregates (Figure 7B). 
No difference was observed between cervical and lumbar expression efficiency at any age or 
between ChAT-IRES-Cre;TardbpF/+ and ChAT-IRES-Cre;TardbpF/F mice at p30, an early age 
preceding neuronal loss (Figure 7B), and CTR expression had no effect on Cre-mediated Tdp-43 
knockout efficiency (Figure 1B). A small proportion of mice (~10%) that survived the initial 
injection later developed symptoms of hydrocephaly first appearing at p25-p30. The type of 
treatment (CTR versus GFP control injection) and genotype of the mouse did not affect risk of 
developing hydrocephaly, suggesting that this represented a delayed complication of the 
injection procedure itself and not a toxic side effect of CTR treatment. All mice displaying 
hydrocephaly symptoms were euthanized and excluded from analysis.   While viral transduction 




chronic toxicity from transgenic protein expression was observed in any major organ system in 
GFP or CTR treated ChAT-IRES-Cre;TardbpF/+ mice at 12 months’ age.  
 
Treatment with CTR Attenuates Behavioral and Pathological Deficits in Mice lacking Tardbp in 
Motor Neurons 
 
A cohort of ChAT-IRES-Cre;TardbpF/F mice (Table 3) injected with our CTR fusion protein gained 
greater weight as compared to their untreated breeder-matched knockout controls (Figures 8B, 
9). Treated ChAT-IRES-Cre;TardbpF/F mice also performed better on the hanging wire and 
accelerating rotarod tests, with a delayed onset and slower progression of motor deficits 
(Figure 8C-E). Consequently, treated ChAT-IRES-Cre;TardbpF/F mice showed a robust extending 
of their lifespan, with a median survival increase of 29 weeks, or 66 percent  (Figure 8A). The 
increase in mortality in CTR-treated Tdp-43 knockout mice coincides in time with the loss of 
visible CTR accumulation (between 8 and 12 months), consistent with a therapeutic benefit of 
CTR. Notably, a cohort of ChAT-IRES-Cre;TardbpF/F mice treated with just the N-terminal 
fragment of TDP-43 showed no such motor improvements, suggesting that splicing repression 
underlies the rescue effect (Figure 13).  
Pathological analysis of a cohort of ChAT-IRES-Cre;TardbpF/+ and ChAT-IRES-Cre;TardbpF/F mice 
revealed that while knockout mice lose 50% of ChAT-positive spinal motor neurons, CTR 
treatment significantly mitigated this motor neuron loss in both cervical and lumbar regions 
(Figure 10). Importantly, with our observed transduction efficiency of ~60%, this motor neuron 




maximum cell-autonomous rescue effect (Figure 10B, dotted line). While L3 dorsal root area 
remained unchanged, L3 ventral spinal root cross-sectional area was also improved in treated 
ChAT-IRES-Cre;TardbpF/F mice (Figures 10C, 11). No change in area of L3 dorsal or ventral roots 
in p30 mice of either genotype was observed. As predicted, treatment with our CTR protein re-
repressed a subset of cryptic exon splicing events as determined by quantitative RT-PCR of 
cryptic exon targets previously identified(Jeong et al., 2017) (Figure 12). Taken together, our 
results support the idea that splicing repression is a major function of TDP-43 in motor neurons, 
suggest that loss of TDP-43-mediated splicing repression underlies neurodegeneration, and 













Although the association of TDP-43 pathology with ALS was disclosed a decade ago(Arai et al., 
2006b; Neumann et al., 2006), the major function of this RNA binding protein in motor neurons 
had remained undefined. We previously showed that TDP-43 helps maintain RNA fidelity by 
repressing aberrant splicing(Ling et al., 2015). This function is compromised in the brains of 
cases of several neurodegenerative diseases, including ALS(Ling et al., 2015; Sun et al., 2017b), 
suggesting that nuclear depletion of TDP-43 may underlie motor neuron degeneration. To 
target nuclear TDP-43 depletion as a potential therapeutic strategy to attenuate motor neuron 
disease, it is necessary to demonstrate that splicing repression is a major function of TDP-43 in 
motor neurons.  This thesis project aimed to address this critical question. First, we confirmed 
that loss of neuronal Tdp-43 led to age-dependent neurodegeneration, behavioral deficits 
consistent with the phenotype of ALS/FTD, and compromised splicing repression in two 
different mouse models of TDP-43 loss of function. Next, to validate an AAV-based therapeutic 
strategy for ALS, we showed that the age-dependent motor neuron degeneration in Tdp-43 
knockout mice could be mitigated by replenishing TDP-43 repression using an alternative 
splicing repressor protein, prolonging robustly the survival of mice lacking Tdp-43 in motor 
neurons. Our results were corroborated by complimentary work in Dr. Liam Chen’s lab in which 
TBPH knockout flies transgenically expressing CTR showed similar improvements in survival, 
behavior, and splicing repression (unpublished). Hence, we establish for the first time in vivo 
that splicing repression is a major role of TDP-43 in motor neurons. Our results also validate a 
novel mechanism-based treatment strategy, in which virally-delivered spicing repressor 




recognized splicing repressor (RAVER1) could potentially improve motor function and extend 
lifespan by restoring splicing repression in motor neurons of ALS patients. Given that nearly all 
cases of sporadic ALS display TDP-43 pathology(Neumann et al., 2006), the lack of observable 
acute or chronic toxicity of the CTR repressor in mice would strongly support the therapeutic 
potential of our AAV-based treatment strategy in the clinic. To date, over 60 molecules 
representing at least 10 broadly defined mechanisms of action have been investigated as 
potential treatments for ALS(Petrov, Mansfield, Moussy, & Hermine, 2017), but the 
overwhelming majority have failed to demonstrate efficacy in clinical trials. These failures over 
the last two decades are testament to the complexity of ALS and the lack of a unifying 
mechanism linking the various molecular and cellular observations in this disease. Our results 
help address this concern by validating a major function of an important disease-related 
protein, TDP-43, setting the stage for future gene therapy trials involving CTR or related 
variants.  
The therapeutic relevance of our rescue approach is strengthened by the recent success of an 
AAV9-based Phase 1 gene therapy clinical trial for spinal muscular atrophy (SMA)(Mendell et al., 
2017). AAV vectors are currently the most common mode of transgene delivery for preclinical 
and clinical trials involving the CNS (for a review of different delivery methods, see Table 4) and 
are chosen primarily for their lack of cytotoxicity, broad host range, and episomal genetic 
incorporation(McMenamin & Wood, 2010; Weinberg et al., 2013). While AAV is capable of 
transducing both dividing and non-dividing cells, transduction with AAV generally results in 
more robust expression in non-dividing cells such as neurons, as episomal genetic material is 




demonstrates neuronal tropism and is able to cross the blood-brain barrier when delivered 
systemically(Chakrabarty et al., 2013; de Backer, Brans, Luijendijk, Garner, & Adan, 2010; Foust 
et al., 2009; Passini & Wolfe, 2001; Swain et al., 2014; Tanguy et al., 2015). Together, these 
characteristics of AAV9 make it a perfect candidate as a vehicle for future gene therapy studies 
to restore TDP-43 mediated splicing repression in humans. 
Our neonatal AAV9-based delivery protocol allowed us to successfully transduce about 60 
percent of ChAT-positive spinal motor neurons, a result consistent with other studies employing 
a similar delivery protocol and viral serotype(McLean et al., 2014; H. Zhang et al., 2011). It is 
important to note that since our mouse model lacked Tdp-43 in >95% of ChAT-positive spinal 
motor neurons (Figure 1), we could not rescue all of these motor neurons, a limitation that 
likely hampered the magnitude of our rescue effect. Furthermore, that the splicing repressor 
domain of RAVER1 was not predicted to fully restore all TDP-43 dependent splicing events(Ling 
et al., 2015), and that the observable accumulation of CTR protein was limited to 8-12 months 
are factors that likely undermined the outcome of this therapeutic strategy. Future experiments 
employing alternative splicing repressors, viral serotypes with higher neuronal tropism, such as 
AAV-PHP-eB(Chan et al., 2017), and alternative delivery methods, such as intravenous or 
intrathecal injections in adult mice, will further validate the therapeutic benefit of our approach 
and help set the stage for future gene therapy clinical trials for ALS. 
We previously demonstrated that cryptic exons are highly variable between different cell types 
and organisms, suggesting that TDP-43 loss may impair cell-type specific pathways in unique 
ways and complicating efforts at developing treatments targeting any particular final 




is highly conserved across species(Ling et al., 2015), making our mechanism-based therapeutic 
approach a more viable strategy. Furthermore, as mislocalization and nuclear clearance of TDP-
43 occurs in a subset of patients with frontotemporal dementia(Neumann et al., 2006), 
inclusion body myopathy(Salajegheh et al., 2009), and Alzheimer’s disease(Amador-Ortiz et al., 
2007), our mechanism-based strategy may hold promise for these diseases as well.  
Our results do not exclude other putative function of TDP-43, as this protein has been 
implicated in a variety of important nuclear and non-nuclear cellular processes besides splicing 
repression, nor do they address the potential toxic effects of cytoplasmic TDP-43 aggregation 
on disease progression. Nuclear TDP-43 depletion is an early event, possibly preceding its 
cytoplasmic aggregation(Vatsavayai et al., 2016b), and while promising therapeutic options for 
reducing TDP-43 aggregation mediated toxicity are being developed(Becker et al., 2017a), 
further effort is needed to clarify the different contributions of toxic gain of function and 
nuclear loss of function of TDP-43 to the pathogenesis of neurodegenerative diseases. 
Assessing the importance of splicing repression in other models of neuronal TDP-43 
dysfunction, such as one expressing transgenic TDP-43 with a nonfunctional nuclear localization 
sequence that sequesters endogenous Tdp-43(Spiller et al., 2016) will improve our 
understanding of the complex interplay between cytoplasmic accumulation and nuclear loss of 
TDP-43.  
In summary, we show that restoring splicing repression in TDP-43 deficient motor neurons in 
mice prolongs survival and attenuates motor neuron disease. Our study not only establishes a 
major role of TDP-43 in motor neurons but also validates a novel mechanism-based therapeutic 























Unknown cause in 90-95 percent of 
cases (termed sALS). Characterized by 
death of upper and lower motor 
neurons, muscle weakness, spasticity, 
and loss of voluntary 
control(Cleveland et al., 2001; del 
Aguila et al., 2003; Julien, 2001) 
Yes Yes 
Primary Lateral 
Sclerosis (PLS)  
Diagnosis of exclusion; unclear if 
actually a slowly progressing form of 






Progressive spasticity in lower limbs 
that can be inherited in autosomal 
dominant (~43%), recessive (~10%), 








90-95% of cases involve genetic 
mutations of SMN1 gene, inducing 
death of lower motor neurons and 
muscle atrophy(Lim & Hertel, 2001; 





Affects neurons innervating bulbar 




Spasticity of bulbar muscles caused by 
damage to corticobulbar 
tract(Grattan-Smith, Hopkins, Shield, 















et al., 2011; Y. 
Yang et al., 2001) 
Alsin 2q33.1 Juvenile ALS Yes 









Annexin A11 10q22.3 ALS Yes 
ATXN2(Becker et 
al., 2017a; Elden 








Rheenen et al., 
2016) 
Leucine-rich repeat 
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FIG4(Chow et al., 




6q21 ALS Yes 
FUS(Baumer et al., 
2010; Urwin et al., 
2010; Vance et al., 
2009) 































NEK1(Kenna et al., 
2016) 





et al., 2013) 
Optineurin 10p13 ALS, glaucoma Yes 
PFN1(Tanaka & 
Hasegawa, 2016; 
C. Wu et al., 2012) 
Profilin-1 12p13.2 ALS Yes 
PRPH(Corrado et 
al., 2011) 
Peripherin 12q13.12 ALS Unknown 
SCFD1(van 




14q12 ALS Unknown 
SETX(Hirano et al., 
2011) 





SOD1(Jones et al., 
1993; Mackenzie 











Mao, & Hu, 2011; 
Fecto et al., 2011) 
p62/sequestome 5q35.3 ALS, FTD Yes 
TARDBP(Arai et 
al., 2006b; 
Neumann et al., 
2006; Rutherford 
et al., 2008) 
Tar DNA-binding 










TBK1(Cirulli et al., 
2015b; Freischmidt 
et al., 2015) 
TANK-binding kinase 
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12q14.2 ALS Yes 
















& Tibbetts, 2010) 
Ubiquilin2 Xp11 ALS, FTD Yes 
VAPB(Kanekura, 
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Cohort 1 11 (2♀) 11 (7♀) 8 (3♀) 8 (5♀) 
Cohort 2 9 (6♀) 11 (3♀) 12 (6♀) 6 (2♀) 
P90 pathology 
analysis cohort 

















6 (2♀) 3(2♀) 4 (2♀) 4 (2♀) 
 
Table 3: Final sample sizes for all mouse cohorts examined in this study, separated by genotype 





Table 4: Gene therapy delivery vehicles for preclinical and clinical CNS disease therapeutic trials 
(Donde, Wong, & Chen, 2017) 
Delivery Vehicle Benefits Drawbacks 
Adeno-associated virus 
(AAV)(Burger et al., 2004; 
Chakrabarty et al., 2013; de 
Backer et al., 2010; Foust et 
al., 2009; Howard et al., 
2008; Kaplitt et al., 1994) 
Wide variety of pseudotypes 
for neuron and glia-specific 
targeting 
Robust expression after 
several months 
Episomal incorporation 
reduces risk of harmful 
insertion 
Some serotypes can cross 
BBB when injected 
systemically 
~4.5 kb carrying capacity 
complicates large/multiple 
transgenes and CRISPR 
delivery 
Reactive astrogliosis possible 
Expensive to produce 
Episomal incorporation is 
less efficient in dividing cells 
Safety concerns about 
mutations restoring viral 
replication competency 
Retrovirus(Cannon, Sew, 
Montero, Burton, & 
Greenamyre, 2011; Cockrell & 
Kafri, 2007; Evans & Garcia, 
2000; Naldini, Blmer, Gage, 
Trono, & Verma, 1996) 
Larger carrying capacity (~9 
kb) 
Easier and cheaper to 
produce than AAV 
Wide variety of pseudotypes 
for neuron and glia-specific 
targeting 
Insertion into host genome 
allows transduction of 
replicating cells 
Safety concerns about 
insertional mutagenesis 
Safety concerns about 
mutations restoring viral 
replication competency 
Does not cross BBB when 
injected systemically 
Reactive astrogliosis possible 
In-utero 
electroporation(Davtyan et 
al., 2012; Taniguchi, Young-
Pearse, Sawa, & Kamiya, 
2012) 
Cheaper to produce than 
viral vectors 
Limited cell type targeting 
based on timing of 
electroporation 
Low immuogenicity 
Limited to prenatal animal 
models 
Episomal incorporation is 
less efficient in dividing cells 
 
Synthetic vectors(Aktas et 
al., 2005; Koltover, Salditt, 
Rdler, & Safinya, 1998; 
Mamot et al., 2004; Pack, 
Hoffman, Pun, & Stayton, 
2005; Shyam et al., 2015) 
Cheaper to produce than 
viral vectors 
Low immunogenicity 
>10kb carrying capacity 
More transient expression 
profile 
Low in-vivo efficiency 
Antisense 
oligonucleotides(Aartsma-
Cheap and easy to produce 





Rus, 2017; Becker et al., 
2017b; Corey, 2017; DeVos et 
al., 2013; Donnelly et al., 
2013; Miller et al., 2013; 
Passini et al., 2011) 
Widespread cellular uptake 
in the CNS 
Cannot easily cross the BBB 
when delivered systemically 












Figure 1 Legend: (A) Schematic of ChAT-IRES-Cre and TardbpF/F alleles in our conditional Tdp-43 
knockout mouse. Cre-mediated excision of exon 3 leads to nonsense-mediated decay of the 
mRNA transcript. (B) Immunofluorescent stain of ChAT (red) and Tdp-43 (blue) in p30 ChAT-
IRES-Cre;TardbpF/+ mice, CTR treated and untreated ChAT-IRES-Cre;TardbpF/F mice. In all three 
groups, Cre-dependent Tdp-43 knockout rate was ~95% in both cervical and lumbar sections 











Figure 2 Legend: (A) Progressive motor neuron loss in ChAT-IRES-Cre;TardbpF/F mice; lumbar 
spinal sections were immunostained against ChAT (see Figures 9 and 10 for examples). Few 
ChAT-positive neurons remain in the ventral horn of 7-month-old knockout mice (*p < 0.05). (B) 
Transverse sections of L4 dorsal and ventral roots. Loss of large motor axons in the ventral roots 
of 7 month old ChAT-IRES-Cre;TardbpF/F mice is evident. No change is observed at 1 month 
Scale bar: 50μm, first and second panels, 20μm, third panel. (C) Distribution of ventral root 
axon feret diameter at 1 and 7 months for ChAT-IRES-Cre;TardbpF/F mice (green) and ChAT-IRES-
Cre;TardbpF/+ control mice (blue). The total number of axons was unchanged at 1 month and 












Figure 3 Legend: (A) Gene diagram of CaMKIIa-CreER and Tdp-43F/F alleles. Administration of 
tamoxifen leads to Cre-mediated excision of Tdp-43 exon 3, and subsequent mRNA degradation 
through nonsense mediated decay (NMD). (B) TDP-43 N-terminal (red) with hematoxylin 
counterstain (blue) for representative CaMKIIa-CreER;TardbpF/+  control mice (termed ‘wt’) and 
CaMKIIa-CreER;TardbpF/F knockout mice (termed ‘cT’) sections at 3 months of age in the 
hippocampus. (C) TDP-43 C-terminal (green) and NeuN (red) staining in the frontal cortex of 
representative sections from wt and cT mice. Dashed lines mark the boundaries of the cortical 
layers, numbered on the left side. Arrowheads indicate some neurons (NeuN, red) without 
visible TDP-43 staining. Scale bars b 200 μm, c 100 μm. (D) Quantifications of % neurons 
(NeuN+) expressing detectable TDP-43 in the hippocampus and the cortical layers of wt and cT 
at 3 months of age. TDP-43 is lost in 80% of pyramidal neurons in the hippocampus and cortex 
layers 2/3 and 4, and ~40% of pyramidal neurons in cortex layers 5 and 6 (N = 6 wt, 5 cT)(LaClair 












Figure 4 Legend: Tdp-43 loss leads to selective vulnerability in hippocampal CA3/2 and cortical 
Layer II/III and V neurons, and cognitive and behavioral abnormalities. (A) Progressive 
hippocampal and cortical atrophy in cT mice, with cortical thinning and severe CA3/2 cell loss 
(arrows) at indicated ages. (B) Regional volume in cT mice is reduced in hippocampus (Hp) [ F 
(1,11) = 18.836, *** p = 0.001], cortex (Ctx) [ F (1,11) = 46.435, *** p < 0.001], and corpus 
callosum (CC) [Welch(1,5.505) = 19.470, ** p = 0.001], but not cerebellum (Cb) [ F (1,11) = 
0.066, p = 0.803], compared to wt at 8 months (n : wt = 5, ct = 8). (C) Selective degeneration of 
CA3/2 neurons in cT mice (some indicated by arrows) at 4 months, while CA1 and DG are 
unaffected. (D) CA3/2 neurons are selectively lost at 6 months [ t (10) = 3.428, ** p = 0.002; wt 
(M = 182.42, SD = 54.41), cT (M = 104.62, SD = 11.37)], followed by the dentate gyrus (DG) at 14 
months (t (14) = 2.339, * p = 0.035) while CA1 neurons are unchanged [ t (14) = 1.843, p = 
0.087]. (3 and 6 m n = 6; 14 m n = 8). (E) CV staining in the cortical layers at 3 months of age. 
Degenerating neurons (black arrows) are numerous in layers III and V of cT mice, in contrast to 
normal neurons (open arrows). Insets show magnified healthy (open arrows) vs degenerating 
neurons (black arrows) in layer V. (F) Quantification of morphologically healthy neurons 
revealed that neurons degenerate significantly in cortical layers 2/3 and 5, but not 4 and 6 in 3-
month-old cT mice compared to wt. [Layer 2/3 F (1,7) = 11.653, p = 0.011*; Layer 4 F (1,7) = 
0.046, p = 0.836 NS; Layer 5 F (1,7) = 23.399, p = 0.002**; Layer 6 F (1,7) = 0.354, p = 0.570 NS] 













Figure 5 Legend: Performance of cT and wt mice in the elevated plus maze and the Y-maze. Left 
cT mice show increased time in the open arm of the elevated plus maze by 14 months of age 
compared to wt littermates (p < 0.001). Middle cT mice show significantly reduced spontaneous 
alternation in the Y-maze by 6 months of age compared to wt littermates (p = 0.043). Right total 
number of arm entries in the Y-maze does not differ between cT and wt mice, even at 14 m (p = 











Figure 6 legend: (A) Schematic showing the locating of the cryptic exon and primers in adjacent 
annotated exons (not to scale). (B) RT-PCR validation of two cryptic exons (red arrows) in the 
Ap3b2 and Camk1g transcripts in RNA extracted from hippocampi of 3 month old CaMKIIα-










Figure 7 Legend: (A) Quantification of nuclear CTR in ChAT-positive neurons in ChAT-IRES-
Cre;TardbpF/+ mice in cervical (green), lumbar (red), and dorsal horn neurons (blue). Our 
protocol allowed for a ~60% efficiency of targeting motor neurons until at least 8 months, with 
no difference observed between cervical and lumbar regions. (N=3 animals per time point, 5 
spinal sections per region per animal, scale bar = 100 µm). (B) Immunostaining of ChAT (red) 
and CTR (recognized by human-specific N-terminal TDP-43 antibody, green) in representative 
lumbar ventral horn sections of ChAT-IRES-Cre;TardbpF/+ and ChAT-IRES-Cre;TardbpF/F mice.  (C) 
Diagram of the CTR chimeric protein construct packaged in AAV9, with the N-terminal fragment 
of human TDP-43 (orange), the splicing repression domain of RAVER1 (blue), and the 3’ 













Figure 8 Legend: Expression of CTR in Tdp-43 knockout mice prolong survival and attenuates 
behavioral deficits. (A) Kaplan-Meier survival curve of ChAT-IRES-Cre;TardbpF/+ and ChAT-IRES-
Cre;TardbpF/F mice administered AAV9 containing either CTR (treated) or GFP control 
(untreated). Data from both cohorts are shown together. Median untreated ChAT-IRES-
Cre;TardbpF/F survival was extended from 44 weeks to 73 weeks in treated mice (p < 0.001 for 
all analyses). (B) CTR treatment mitigated the age-dependent body weight loss of knockout 
mice while having no effect on control mice. Hanging wire (C) and rotarod performance (D) 
show a mitigation of motor deficits in CTR-treated knockout mice compared to untreated 
controls (*p < 0.05, ** p < 0.01, *** p < 0.001, Tukey’s multiple comparison test). Progression 
of hanging wire deficits was also significantly attenuated in CTR-treated mice (untreated 
slope=-1.19, CTR slope= -0.68, p < 0.01) (E) Kaplan-Meier survival curve of onset of motor 
dysfunction, as defined as two consecutive weeks of <60s hanging wire time. Onset was 










Figure 9 Legend: Body weights for CTR treated and untreated ChAT-IRES-Cre;TardbpF/+ and 
















Figure 10 Legend: Expression of CTR in Tdp-43 knockout mice attenuates motor neuron loss and 
restores splicing repression. (A) Representative ChAT immunostaining of an L3 lumbar ventral 
horn section. (scale bar = 100 µm). (B) Quantification of ChAT-positive motor neurons in CTR-
treated (blue) and untreated (red) knockout mice. As no difference was observed between CTR-
treated and untreated ChAT-IRES-Cre;TardbpF/+ mice, results are shown as a percentage of each 
group’s respective control. Untreated knockout mice showed a 50% decrease in motor neuron 
number at p90, whereas the motor neuron abundance of CTR-treated knockout mice is 63% 
(lumbar) and 61% (cervical) of controls (*p < 0.05). With a transduction efficiency of 60 percent, 
a complete cell-autonomous rescue of motor neuron death by CTR would still only result in a 
motor neuron rescue of ~80% (dashed line). (C) Quantification of cross-sectional area. Ventral, 
but not dorsal, root area was diminished in untreated ChAT-IRES-Cre;TardbpF/F mice and 










Figure 11 Legend: Representative cresyl violet stained dorsal and ventral L3 roots. Ventral, but 
not dorsal, root area was diminished in untreated ChAT-IRES-Cre;TardbpF/F mice and restored 










Figure 12 Legend: Relative levels of three cryptic exon mRNA targets predicted to be 
incorporated in Tdp-43 deficient motor neurons in p45 mice, normalized to an average of 
GAPDH and TBP genes as determined by quantitative RT-PCR. A reduction in SYNJ2BP and IFT81 
cryptic exon incorporation (but not GGCT) was observed in CTR-treated ChAT-IRES-











Figure 13 Legend: Hanging wire performance of mice administered AAV9 containing the N-
terminal fragment of TDP-43 alone (NTF, blue line) showed no improvement over untreated 
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